[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576986":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":39,"responsibleParty":56,"collaborators":26,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":26,"enrollmentInfo":71,"targetDuration":26,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":42,"whyStopped":26,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Glostrup University Hospital, Copenhagen","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral Semaglutide","EXPERIMENTAL","Participants are given oral semaglutide once daily.",[13],"Drug: Oral semaglutide",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants are given oral placebo once daily.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Oral semaglutide","Participants will receive oral semaglutide once daily.\n\n1. Starting dose 3 mg\u002Fday for one month (day 1-28)\n2. Intermediate dose 7 mg\u002Fday for one month (day 29-56)\n3. Maintenance dose 14 mg\u002Fday (day 57-182)",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Participants will receive an oral placebo once daily.\n\n1. Placebo tablets received on visit 1 (baseline) for one month (day 1-28)\n2. Placebo tablets received on visit 2 (month 1) for one month (day 29-56)\n3. Placebo tablets received on visit 3 (month 2) for four months (day 57-182)",[15],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Miriam Kolko, MD, PhD","CONTACT","+45 29807667","miriamk@sund.ku.dk",{"name":37,"role":33,"phone":26,"phoneExt":26,"email":38},"Anna-Sophie Thein","anna-sophie.thein@sund.ku.dk",[40],{"facility":41,"status":42,"city":43,"state":26,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Department of Ophthalmology, Rigshospitalet","RECRUITING","Glostrup Municipality","2600","Denmark","DK",{"type":48,"coordinates":49},"Point",[50,51],12.40377,55.6666,{"lat":51,"lon":50},[54],{"name":55,"role":33,"phone":34,"phoneExt":26,"email":35},"Miriam Kolko, MD, PhD, Professor, Consultant",{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":60,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Miriam Kolko","Professor in Translational Eye Research, Chief Physician.","Rigshospitalet, Denmark","100576986","phase-4-a-study-investigating-oral-semaglutide-in-people-with-open-angle-glaucoma-100576986",false,"NCT06792422","A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma","Additive Benefits of Semaglutide for Open-AngLe Glaucoma - an Opportunity for Neuroprotection","ABSALON","Inclusion Criteria:\n\n* Ability to read and speak Danish\n* 45 years or older at the time of inclusion\n* Visual acuity equal to or above 0.5 in the study eye\n* Diagnosis of POAG with MD ≤ 16 dB with repeatable and reliable (false positive less than 15 %) VF loss measured by standard automated perimetry on at least one eye\n* Receiving IOP-lowering glaucoma treatment\n* Nerve fiber layer defects identified by OCT\n\nExclusion Criteria:\n\n* Diabetes or renal impairment\n* Medical history of significant eye disease (including ocular trauma) other than glaucoma\n* Ocular inflammation\u002Finfection within three months from inclusion\n* Intraocular surgery 3 months before inclusion\n* Smoker at the time of inclusion\n* Pregnant or breast-feeding\n* Females of childbearing potential who are not using adequate contraceptive, which includes the following: Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal, progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable; Intrauterine device (IUD); Intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomised partner; Sexual abstinence\n* Subjects allergic to drug ingredients administered during the trial\n* Subjects with untreated severe systemic disease or malignancies\n* Previous history of pancreatitis\n* BMI \\\u003C 18.5\n* Subjects receiving treatment with: Dipeptidyl peptidase-4 inhibitors; Other GLP-1RAs; Insulin; Insulin analogues; Sulfonylurea; Systemic corticosteroids; Immunosuppressants","ALL","45 Years",{"count":72,"type":73},126,"ESTIMATED","INTERVENTIONAL",[76],"PHASE4","The aim of this clinical trial is to investigate whether oral semaglutide can be used to treat open-angle glaucoma. The main question it aims to answer is: Does oral semaglutide safely improve inner retinal function in patients with open-angle glaucoma as measured by the photopic negative response of the electroretinogram.\n\nResearchers will compare oral semaglutide to a placebo (a look-alike substance that contains no drug).\n\nParticipants will:\n\n* Take semaglutide or a placebo every day for 6 months.\n* Visit the clinic 5 times in total for tests and interviews: At baseline (the first day they are included in the study), after 1 month, after 2 months, after 3 months, and after 6 months (the last day they are included in the study).",[79,80,81],"Primary Open Angle Glaucoma (POAG)","Open-Angle Glaucoma","Glaucoma",[81,83,84,85,86,87,88],"Semaglutide","Rybelsus","Primary Open Angle Glaucoma","GLP-1RA","Photopic Negative Response","GLP-1","2025-01-20",{"date":91,"type":92},"2025-01-24","ACTUAL",{"date":94,"type":73},"2025-01",{"date":96,"type":73},"2028-12",{"name":5,"class":6},1]